Navigation Links
Enbrel® (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis
Date:2/4/2011

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La.  

"At least half of people with plaque psoriasis have involvement on their scalp, which may contribute to feelings of embarrassment associated with this condition," said lead author Jerry Bagel, M.D., medical director, Psoriasis Treatment Center of Central New Jersey. "These data reinforce the efficacy and safety profile of ENBREL for adult patients with moderate to severe plaque psoriasis with scalp involvement."

In this trial, patients were randomized to either 12 weeks of ENBREL 50 mg twice weekly followed by 12 weeks of ENBREL 50 mg once weekly (Group A), or 12 weeks of placebo twice weekly followed by 12 weeks of ENBREL 50 mg twice weekly (Group B). This trial met its primary endpoint of mean percent improvement from baseline in Psoriasis Scalp Severity Index (PSSI) with 87 percent PSSI improvement in Group A compared with 20 percent in Group B at week 12 (P<0.0001). The PSSI response to ENBREL for patients in Group A was maintained through 24 weeks despite patients switching to a lower dose (91 percent). Patients in Group B saw a mean percent improvement in their PSSI score of 79 percent at week 24, similar to that achieved by the Group A patients at week 12.

In addition to the improvement in scalp involvement, in an exploratory analysis, the mean percent improvement from baseline in Psoriasis Area Severity Index (PASI) was 74
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
2. New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
3. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
4. Correction: New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
5. New Mexico Software Unveils Additional Software Significantly Expanding Availability of Its Telemedicine Services
6. Study Shows BSGI/MBI Contributes Significantly to Patient Management with Its Ability to Detect Breast Cancer in Difficult to Diagnose Patients
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
9. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
10. CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times
11. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... 2014  Eli Lilly and Company (NYSE: LLY)  ... -- being studied for the treatment of systemic ... due to insufficient efficacy in two pivotal Phase ... safety concerns. ­­­­ In the ILLUMINATE ... endpoint, at either dose studied, of statistically significant ...
(Date:10/2/2014)... plc (NYSE: PRGO ; TASE), a public limited ... (the " Company "), today announced the expiration of ... of its new 1.30% Senior Notes due 2016 (the " ... Notes due 2018 (the " 2018 Exchange Notes "), $800,000,000 ... 2023 Exchange Notes ") and $400,000,000 of its new 5.30% ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4
... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:10/1/2014)... to keep their "eyes on the prize" may be ... staying focused on a specific target ahead can make ... walk there faster, psychology researchers have found. Their study, ... the environment naturally, offers a new strategy to improve ... in exercise if physical activity seems daunting, which can ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining how ... Senior citizens can purchase a joint life insurance policy ... joint policy is cheaper, but will only pay benefits ... insurance can be used to cover important funeral expenses. ... as the application process is simple and straightforward. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Bedros Keuilian ... Body Boot Camp fitness boot camps, he’s also considered ... training , with sold out business summits, a line ... marketing consultant to a recent Spike TV reality show ... that now is the time for personal trainers and ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... and ATLANTA (PRWEB) October 01, 2014 ... security executive networking and relationship-marketing firm, announced ... Information Security Executive® and Project of the ... top-ranking decision makers representing organizations in financial ... Projects include large-scale technology endeavors that address ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7
... Nov. 19 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... as senior vice president, operations. "We are ... and,supply chain management to our already strong senior ... and chief operating,officer. Ms. Ellerbrock, 46, joins ...
... up on a study that found widespread failures in ... team from the Johns Hopkins Childrens Center and Duke ... more than a mock trauma drill to diagnose the ... sharp again. Their report appears in the November issue ...
... rose , , MONDAY, Nov. 19 (HealthDay News) -- A new ... on the body, which may explain why people of lower ... report. , The link between higher levels of inflammatory molecules ... by poor diet and lack of exercise, the study suggests. ...
... are adding to the obesity crisis its fruit drinks, ... of North Carolina at Chapel Hill School of Public Health ... cider are abundant, the problem can be even more apparent. ... adults get through beverages has nearly doubled, according to a ...
... PHILADELPHIA According to a study that appears in ... Neuroscience), researchers at the University of Pennsylvania School of ... neural responses to psychological stress. , We ... different spatial and temporal profiles for men and women ...
... 2007 Campaign highlighted by new partnership with the NFL ... Romano, Antonio Banderas, New Orleans Saints, Reggie Bush and Marlo ... will also launch in ... Jude Children,s Research Hospital,has launched its 2007 Thanks and Giving ...
Cached Medicine News:Health News:Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations 2Health News:'Mock' drills boost child resuscitation skills in 'failing' adult emergency rooms 2Health News:'Mock' drills boost child resuscitation skills in 'failing' adult emergency rooms 3Health News:Researchers Spot Link Between Heart Disease, Income 2Health News:Doubled calorie intake from beverages likely contributes to adult obesity 2Health News:Doubled calorie intake from beverages likely contributes to adult obesity 3Health News:Penn researchers use brain imaging to demonstrate how men and women cope differently under stress 2Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 2Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 3Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 4Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 5Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 6
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: